68Ga-DFC413

Phase 1

68Ga-DFC413 is one of 6 therapeutic programs targeting Pancreatic Ductal Adenocarcinoma (PDAC). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Phase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Pancreatic Ductal Adenocarcinoma (PDAC)

#DrugCompanyPhaseTrials

Fotivda

Roche

Phase 2

1 2

Erbitux

IImclone

Phase 2

1 3

[18f]fapi-74 Pet/ct

SSOFIE

Phase 3

1 4

VS-7375

VVerastem, Inc.

Phase 2

1 5

BT5528

BBicycleTx Limited

Phase 2

1 6

68Ga-DFC413

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07630961

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

Phase I, Open Label First in Human Study to Evaluate the Imaging Characteristics, Safety, Biodistribution and Pharmacokinetics of JFI447 [68Ga]Ga-DFC413, and Compare to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Recruiting· Novartis logo

Novartis·Phase 1·NCT07630961·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 68Ga-DFC413. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 68Ga-DFC413. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novartis

68Ga-DFC413

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

References

Drug Info

Quick Facts

Related News